文献速递新药、器械与细胞基因治疗研发临床试验与 GCP

Betibeglogene Autotemcel基因治疗非β0/β0基因型β地中海贫血

Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia.
PubMed 文献 · N Engl J Med · 2021-12-11

这项开放标签3期研究评估了beti-cel在非β0/β0基因型输血依赖型β地中海贫血成人和儿童患者中的疗效与安全性。23例患者接受busulfan清髓后静脉输注beti-cel,中位随访29.5个月,可评估的22例中20例(91%)实现输血独立,包括7例小于12岁患者中的6例(86%)。

要点

  • 可评估患者中91%(20/22)实现输血独立,包括86%(6/7)的12岁以下患者。
  • 输血独立期间平均血红蛋白为11.7 g/dL(范围9.5至12.8)。
  • 安全性特征与busulfan清髓一致,未见癌症病例。

核心结论

  • beti-cel治疗使大多数非β0/β0基因型患者(包括12岁以下儿童)获得持续HbAT87Q水平和足以实现输血独立的总血红蛋白水平。

研究设计与样本

  • 开放标签3期研究,纳入输血依赖型β地中海贫血且为非β0/β0基因型的成人和儿童患者,共23例入组并接受治疗。
  • 患者接受基于药代动力学分析调整剂量的busulfan清髓后静脉输注beti-cel。
  • 主要终点为输血独立,即在不输注红细胞的情况下加权平均血红蛋白水平≥9 g/dL持续≥12个月。

主要发现

  • 中位随访29.5个月(范围13.0至48.2)。
  • 可评估的22例患者中20例(91%)实现输血独立,其中小于12岁患者7例中6例(86%)实现输血独立。
  • 输血独立期间平均血红蛋白水平为11.7 g/dL(范围9.5至12.8)。
  • beti-cel输注后12个月,实现输血独立患者的基因治疗来源成人血红蛋白(HbAT87Q)中位水平为8.7 g/dL(范围5.2至10.6)。
  • 4例患者发生至少1起研究者认为与beti-cel相关或可能相关的不良事件,除1例血小板减少症外均为非严重事件;未观察到癌症病例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Betibeglogene autotemcel (beti-cel) gene therapy for transfusion-dependent β-thalassemia contains autologous CD34+ hematopoietic stem cells and progenitor cells transduced with the BB305 lentiviral vector encoding the β-globin (βA-T87Q) gene. METHODS: In this open-label, phase 3 study, we evaluated the efficacy and safety of beti-cel in adult and pediatric patients with transfusion-dependent β-thalassemia and a non-β0/β0 genotype. Patients underwent myeloablation with busulfan (with doses adjusted on the basis of pharmacokinetic analysis) and received beti-cel intravenously. The primary end point was transfusion independence (i.e., a weighted average hemoglobin level of ≥9 g per deciliter without red-cell transfusions for ≥12 months). RESULTS: A total of 23 patients were enrolled and received treatment, with a median follow-up of 29.5 months (range, 13.0 to 48.2). Transfusion independence occurred in 20 of 22 patients who could be evaluated (91%), including 6 of 7 patients (86%) who were younger than 12 years of age. The average hemoglobin level during transfusion independence was 11.7 g per deciliter (range, 9.5 to 12.8). Twelve months after beti-cel infusion, the median level of gene therapy-derived adult hemoglobin (HbA) with a T87Q amino acid substitution (HbAT87Q) was 8.7 g per deciliter (range, 5.2 to 10.6) in patients who had transfusion independence. The safety profile of beti-cel was consistent with that of busulfan-based myeloablation. Four patients had at least one adverse event that was considered by the investigators to be related or possibly related to beti-cel; all events were nonserious except for thrombocytopenia (in 1 patient). No cases of cancer were observed. CONCLUSIONS: Treatment with beti-cel resulted in a sustained HbAT87Q level and a total hemoglobin level that was high enough to enable transfusion independence in most patients with a non-β0/β0 genotype, including those younger than 12 years of age. (Funded by Bluebird Bio; HGB-207 ClinicalTrials.gov number, NCT02906202.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Locatelli F, Thompson AA, Kwiatkowski JL, et al. Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia. N Engl J Med. 2021. PMID: 34891223. doi:10.1056/NEJMoa2113206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。